Business
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the
About this update from Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa. , Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET . The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page . A replay of the webcast will be available after the event. About Madrigal Pharmaceuticals Madrigal Pharmaceuticals , Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com . Investor Contact Tina Ventura , [email protected] Media Contact Christopher Frates, [email protected] Source: Madrigal Pharmaceuticals, Inc.
View stock analysis, news, and events for Madrigal Pharmaceuticals, Inc.